Yissum - Research Development Company of the Hebrew University

Ceramide Analogs as Apoptotic Agents in Prostate Cancer

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cluster8

Novel ceramide analogs with effects on pure acid ceramidase activity. These novel compounds were found to inhibit both the degradation (“forward” reaction) and synthesis (“reverse” reaction) of BODIPY-conjugated and/or 14C-labeled C12 ceramide by this enzyme. In addition these these compounds were tested in in vivo models in mice. Notably, each compound was highly toxic to the cells, and induced apoptotic cell death as judged by Caspase 3 activation. Moreover, each compound led to an elevation of cellular ceramide via multiple effects on sphingolipid metabolism. At least three of these effects (inhibition of acid ceramidase activity, inhibition of sphingomyelin synthesis, and inhibition of glycosphingolipid synthesis) could lead to an elevation of cellular ceramide, explaining the potent pro-apoptotic activity and their potential use as anti cancer leads.

Project ID : 12-2006-594

Description of the technology

Validated approach in small animals and human cell models

Categories

Ceramide, apoptosis, cancer, sphingolipids, prostate cancer

Development Stage

Considerable anticancer activity in vivo in prostate, colon, pancreas and melanoma mouse models of human tumors. In vitro activity in various human cancer cell lines.

Highlights

  • Novel new compounds
  • Considerable anticancer activity observed with local or even in metastatic cancer of prostate, colon, pancreas and melanoma mice models. Analog were injected intradermally or intraperitoneally or given per os to mice bearing human tumors.
  • Provides powerful stand alone or adjunctive therapy with irradiation or chemotherapy for cancer
  • Elevates cellular ceramide, inducing cytotoxicity and death by apoptosis
  • Leverages proven treatment models

Our Innovation

  • Synthetic compounds activate procaspase-3 and induceapoptosis
  • Increases the caspase-3 activity six to seven fold
  • Treatment with an analogue resulted in tumor regression in mice

The Opportunity

  • Higher efficiency for cancer treatment
  • Attenuates treatment process, reducing patient discomfort
  • Addresses needs for further expand to cancer market

Development Milestones

  • Further in vivo mouse models
  • Pharmacokinetic pharmacodynamic experiments
  • Progress to In vivo human testing

Project manager

Ariela Markel
VP, Business Development, Healthcare

Project researchers

Arie Dagan
HUJI, School of Medicine - IMRIC

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Express Licensing
  • Oncology / Cancer

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.